Practice Changing Studies in Melanoma

Feb 21, 2022

In this episode of SurgOnc Today, Tina Hieken, MD, from the Mayo Clinc, in Rochester, MN interviews Georgia Beasley, MD, MHS, from Duke University in Durham, NC and Christina Stevenson, MD, MS, from the University of Connecticut in Farmington, CT. They review the following studies and how their findings are important to surgical oncologists specializing in melanoma.

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

LBA3_PR - Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma